Blood Purification Equipment Market Size will grow between 2022 and 2028 due to increasing cases of kidney failure and the prevalence of autoimmune diseases. A host of therapeutic developments has encouraged leading companies to invest in blood purification devices.
Organizations perform blood purification through filtration, dialysis or adsorption, enabling various kinds of immune disorders, renal failure, inflammatory situations and blood viscosity. In a bid to provide seamless services, hospitals, clinics and other healthcare facilities are likely to invest in advanced blood purification equipment. Industry players are expected to seek portable and stationary devices for continuous blood purification, hemodialysis and hemoperfusion.
Based on application, continuous blood purification equipment will account for a considerable share of global market from 2028. With the demand for continuous renal replacement therapy, the equipment will be trendier. Besides, continuous blood purification is likely to boost the prognosis of patients suffering from multiple organ failure.
With respect to end-users, blood purification equipment market share from hospitals will expand owing to robust government policies. The penetration of stationary blood purification equipment will be noticeable across hospital settings. Besides, the prevalence of chronic diseases will further escalate the demand for the equipment in the end-use sector. Notably, diabetic hospitalization of patients will expedite equipment adoption over the next few years.
North America blood purification equipment market will be strong with the U.S. witnessing an increased demand for hemodialysis. A notable surge in the chronic dialysis population has prompted regional leaders to invest in advances in technology to facilitate the applications of renal replacement therapy. Clinical practices and R&D activities are likely to boost the penetration of dialysis technology.
The competitive landscape of global market indicates leading companies are likely to invest in organic and inorganic strategies, including mergers & acquisitions, product launches, R&D activities and innovations. NxStage Medical Inc., Accel Diagnostics LLC., Toray Medical Co Ltd., Stellarray, Inc., CytoSorbents Corp, Circle Biologics, LLC, Aethlon Medical Inc, Cerus Corp Company, Jafron, Stellarray, Inc., Medtronic and Spectral Medical Inc., are some of the key participants in the landscape.
In April 2020, Medtronic said it won U.S. FDA nod for 1st blood filtration device for children with certain kidney conditions. The Dublin-based Medtronic got the approval of the Carpediem system as renal replacement therapy for critically ill children.
Governments and health governing bodies have exhibited profound traction for blood purification devices. In July 2021, the U.S. FDA stated that blood purification devices could be effective at treating certain patients with confirmed COVID-19 by minimizing cytokines, pathogens and other inflammatory mediators. In April 2020, the U.S. FDA had issued an emergency use authorization (EUA) for a blood purification system to treat patients 18 years of age or older with confirmed COVID-19 with imminent or confirmed respiratory failure. The current trend suggests industry players will continue to invest in blood purification devices globally.
Soaring cases of high blood pressure and the diabetic population will further the demand for advanced blood purification devices. Technological advancements are likely to boost the penetration of portable and stationary purification equipment.
Market, By Application
Market, By Type
Market, By End-users
The above information is provided for the following regions and countries: